Center for biologics evaluation and research (cber), biologics effectiveness and safety (best) initiative: development of new and innovative methods for automated reporting for cber-regulated…
Ended Awarded Last action
- Contract number
- 75F40118D10053
- Awardee
-
International Business Machines Corporation UEI VV9KH3L99VE3 Part of International Business Machines Corporation
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Task orders
- 4 $36,924,291 obligated
Award facts
- Opportunity
-
- FDA18223SOL1196210 Solicitation number
- Biologics Effectiveness and Safety (BEST) Initiative: Development of New and Innovative Methods for Automated Reporting for CBER-Regulated Products Award Notice · Posted May 25, 2018
- Combined order value
- $36,924,291 Current and potential, with all options
- Last date to order 100% complete
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 518210 Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This Indefinite Delivery Contract was awarded by the Food and Drug Administration (FDA) to International Business Machines Corporation (IBM) to support the Center for Biologics Evaluation and Research (CBER) Biologics Effectiveness and Safety (BEST) Initiative. The contract aims to develop new and innovative methods for automated reporting for CBER-regulated biological products.
The contract has a total ceiling value of $37.9 million and is structured as a multiple award, time and materials Indefinite Delivery Contract with a period of performance through September 2023. IBM, as the prime contractor, will provide the FDA's CBER division with IT services and solutions to modernize biological product monitoring and safety surveillance systems. This work is critical to the FDA's oversight of biologics, including cell and gene therapies, blood products, and vaccines. The contract does not have a set-aside designation, as IBM competes effectively in open federal procurement processes for technology services across civilian and defense agencies.
Description
Center for biologics evaluation and research (cber), biologics effectiveness and safety (best) initiative: development of new and innovative methods for automated reporting for cber-regulated biological products.
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$10,000 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $10,000 |
Quick answers
Who was awarded contract 75F40118D10053?
75F40118D10053 was awarded to International Business Machines Corporation by Food and Drug Administration (Department of Health and Human Services) on September 27, 2018.
How much is contract 75F40118D10053 worth?
Orders under 75F40118D10053 have obligated $36,924,291.
How many orders have been placed under contract 75F40118D10053?
4 orders have been placed under 75F40118D10053, the latest on September 27, 2022.
Who can order from contract 75F40118D10053?
75F40118D10053 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75F40118D10053 part of a contract vehicle?
Yes. 75F40118D10053 is part of BEST Initiative - New and Innovative Methods for Automated Reporting.
Was contract 75F40118D10053 competed?
The extent of competition for 75F40118D10053 was full and open competition. The government received 5 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV